Low dose adjuvant angiostatin decreases hepatic micrometastasis in murine ocular melanoma model

Molecular Vision

Volumn 10, Issue , 2004, Pages 987-995

  Yang, Hua ^a   Akor, Charlotte ^a   Dithmar, Stefan ^b   Grossniklaus, Hans E ^a,c  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c EMORY EYE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOSTATIN; KETAMINE; MESSENGER RNA; PHOSPHATE BUFFERED SALINE; PLASMINOGEN; RECOMBINANT PROTEIN; VASCULOTROPIN; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; VASCULAR ENDOTHELIAL GROWTH FACTOR A, MOUSE; VASCULOTROPIN A;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER ADJUVANT THERAPY; CANCER INVASION; CELL MIGRATION; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; DRUG MEGADOSE; ENUCLEATION; EYE TUMOR; IMMUNOCYTOCHEMISTRY; INOCULATION; LIVER METASTASIS; LOW DRUG DOSE; MELANOMA; MELANOMA CELL; MOUSE; MOUSE STRAIN; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SUPPLEMENTATION; TUMOR CELL LINE; WESTERN BLOTTING; ANIMAL; C57BL MOUSE; DISEASE MODEL; EXPERIMENTAL MELANOMA; FEMALE; GENETICS; LIVER TUMOR; METABOLISM; METASTASIS; PATHOLOGY;

ANGIOGENESIS INHIBITORS; ANGIOSTATINS; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; EYE ENUCLEATION; EYE NEOPLASMS; FEMALE; IN SITU NICK-END LABELING; LIVER NEOPLASMS; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; NEOPLASM INVASIVENESS; PLASMINOGEN; RECOMBINANT PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 21244458956     PISSN: 10900535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Zimmerman LE, McLean IW, Foster WD. Does enucleation of the eye containing a malignant melanoma prevent or accelerate the dissemination of tumour cells. Br J Ophthalmol 1978; 62:420-5.
2. Zimmerman LE, McLean IW. An evaluation of enucleation in the management of uveal melanomas. Am J Ophthalmol 1979; 87:741-60.
3. Niederkorn JY. Enucleation in consort with immunologic impairment promotes metastasis of intraocular melanomas in mice. Invest Ophthalmol Vis Sci 1984; 25:1080-6.
4. Grossniklaus HE, Wilson MW, Barron BC, Lynn MJ. Anterior vs posterior intraocular melanoma. Metastatic differences in a murine model. Arch Ophthalmol 1996; 114:1116-20.
5. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100:57-70.
6. Collaborative Ocular Melanoma Study Group. Assessment of metastatic disease status at death in 435 patients with large choroidal melanoma in the Collaborative Ocular Melanoma Study (COMS): COMS report no. 15. Arch Ophthalmol 2001; 119:670-6.
7. Grossniklaus HE. Tumor vascularity and hematogenous metastasis in experimental murine intraocular melanoma. Trans Am Ophthalmol Soc 1998; 96:721-52.
8. Diaz CE, Rusciano D, Dithmar S, Grossniklaus HE. B16LS9 melanoma cells spread to the liver from the murine ocular posterior compartment (PC). Curr Eye Res 1999; 18:125-9.
9. Dithmar SA, Rusciano DA, Armstrong CA, Lynn MJ, Grossniklaus HE. Depletion of NK cell activity results in growth of hepatic micrometastases in a murine ocular melanoma model. Curr Eye Res 1999; 19:426-31.
10. Fidler IJ, Gersten DM, Budmen MB. Characterization in vivo and in vitro of tumor cells selected for resistance to syngeneic lymphocyte-mediated cytotoxicity. Cancer Res 1976; 36:3160-5.
11. Harning R, Szalay J. Ocular metastasis of in vivo and in vitro derived syngeneic murine melanoma. Invest Ophthalmol Vis Sci 1987; 28:1599-604.
12. Rusciano D, Lorenzoni P, Burger M. Murine models of liver metastasis. Invasion Metastasis 1994-95; 14:349-61.
13. Dithmar S, Rusciano D, Grossniklaus HE. A new technique for implantation of tissue culture melanoma cells in a murine model of metastatic ocular melanoma. Melanoma Res 2000; 10:2-8.
14. Aaberg TM Jr, Diaz CE, Margo CE, Grossniklaus HE. Comparison of H&E and S-100 methods for determining metastases in a murine ocular melanoma model. Invest Ophthalmol Vis Sci 1998; 39:S286.
15. Lo KM, Sudo Y, Chen J, Li Y, Lan Y, Kong SM, Chen L, An Q, Gillies SD. High level expression and secretion of Fc-X fusion proteins in mammalian cells. Protein Eng 1998; 11:495-500.
16. O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, Lane WS, Cao Y, Sage EH, Folkman J. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994; 79:315-28.
17. Yang H, Dithmar S, Grossniklaus HE. Interferon alpha 2b decreases hepatic micrometastasis in a murine model of ocular melanoma by activation of intrinsic hepatic natural killer cells. Invest Ophthalmol Vis Sci 2004; 45:2056-64.
18. Apte RS, Niederkorn JY, Mayhew E, Alizadeh H. Angiostatin produced by certain primary uveal melanoma cell lines impedes the development of liver metastases. Arch Ophthalmol 2001; 119:1805-9.
19. Maniotis AJ, Folberg R, Hess A, Seftor EA, Gardner LM, Pe'er J, Trent JM, Meltzer PS, Hendrix MJ. Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am J Pathol 1999; 155:739-52.
20. McDonald DM, Foss AJ. Endothelial cells of tumor vessels: abnormal but not absent. Cancer Metastasis Rev 2000; 19:109-20.
21. Chen X, Maniotis AJ, Majumdar D, Pe'er J, Folberg R. Uveal melanoma cell staining for CD34 and assessment of tumor vascularity. Invest Ophthalmol Vis Sci 2002; 43:2533-9.
22. Folberg R, Pe'er J, Maniotis AJ. Extravascular matrix patterns in uveal melanoma: histogenesis, structure, and molecular regulations. In: Jager M, Niederkorn JY, Ksander BR, editors. Uveal melanoma: a model for exploring fundamental cancer biology. London: Taylor & Francis; 2004. p. 155-68.
23. Boyd SR, Tan DS, de Souza L, Neale MH, Myatt NE, Alexander RA, Robb M, Hungerford JL, Cree IA. Uveal melanomas express vascular endothelial growth factor and basic fibroblast growth factor and support endothelial cell growth. Br J Ophthalmol 2002; 86:440-7.
24. Clarijs R, Schalkwijk L, Ruiter DJ, de Waal RM. Lack of lymphangiogenesis despite coexpression of VEGF-C and its receptor Flt-4 in uveal melanoma. Invest Ophthalmol Vis Sci 2001; 42:1422-8.
25. Boyd S. Uveal melanoma and angiogenesis. In: Jager M, Niederkorn JY, Ksander BR, editors. Uveal melanoma: a model for exploring fundamental cancer biology. London: Taylor & Francis; 2004. p. 125-54.
26. Dithmar S, Diaz CE, Grossniklaus HE. Intraocular melanoma spread to regional lymph nodes: report of two cases. Retina 2000; 20:76-9.
27. Eskelin S, Pyrhonen S, Summanen P, Hahka-Kemppinen M, Kivela T. Tumor doubling times in metastatic malignant melanoma of the uvea: tumor progression before and after treatment. Ophthalmology 2000; 107:1443-9.
28. Kramer TR, McLean IW, Dithmar S, Sharara N, Grossniklaus HE. Vascularization of liver metastases of human uveal melanoma. Invest Ophthalmol Vis Sci 2000; 41:S381.
29. Toivonen P, Makitie T, Kivela T. Microvessels and macrophages in choroidal and ciliary body melanoma. In: Jager M, Niederkorn JY, Ksander BR, editors. Uveal melanoma: a model for exploring fundamental cancer biology. London: Taylor & Francis; 2004. p. 177-190.
30. Holmgren L, O'Reilly MS, Folkman J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med 1995; 1:149-53.
31. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996; 86:353-64.
32. Arbiser JL, Moses MA, Fernandez CA, Ghiso N, Cao Y, Klauber N, Frank D, Brownlee M, Flynn E, Parangi S, Byers HR, Folkman J. Oncogenic H-ras stimulates tumor angiogenesis by two distinct pathways. Proc Natl Acad Sci U S A 1997; 94:861-6.
33. Hendrix MJ, Seftor EA, Chu YW, Seftor RE, Nagle RB, McDaniel KM, Leong SP, Yohem KH, Leibovitz AM, Meyskens FL Jr. Coexpression of vimentin and keratins by human melanoma tumor cells: correlation with invasive and metastatic potential. J Natl Cancer Inst 1992; 84:165-74.
34. Folberg R, Hendrix MJ, Maniotis AJ. Vasculogenic mimicry and tumor angiogenesis. Am J Pathol 2000; 156:361-81.
35. Yang H, Liu P, Freeman J, Grossniklaus HE. Angiostatin expression in human and murine melanoma cell lines. ARVO Annual Meeting; 2002 May 5-10; Fort Lauderdale (FL).
36. Singh AD, Rennie IG, Kivela T, Seregard S, Grossniklaus H. The Zimmerman-McLean-Foster hypothesis: 25 years later. Br J Ophthalmol 2004; 88:962-7.
37. Wu Z, O'Reilly MS, Folkman J, Shing Y. Suppression of tumor growth with recombinant murine angiostatin. Biochem Biophys Res Commun 1997; 236:651-4.
38. Gately S, Twardowski P, Stack MS, Cundiff DL, Grella D, Castellino FJ, Enghild J, Kwaan HC, Lee F, Kramer RA, Volpert O, Bouck N, Soff GA. The mechanism of cancer-mediated conversion of plasminogen to the angiogenesis inhibitor angiostatin. Proc Natl Acad Sci U S A 1997; 94:10868-72.
39. Liu J, Razani B, Tang S, Terman BI, Ware JA, Lisanti MP. Angiogenesis activators and inhibitors differentially regulate caveolin-1 expression and caveolae formation in vascular endothelial cells. Angiogenesis inhibitors block vascular endothelial growth factor-induced down-regulation of caveolin-1. J Biol Chem 1999; 274:15781-5.
40. Stack MS, Gately S, Bafetti LM, Enghild JJ, Soff GA. Angiostatin inhibits endothelial and melanoma cellular invasion by blocking matrix-enhanced plasminogen activation. Biochem J 1999; 340:77-84.
41. Wahl ML, Moser TL, Pizzo SV. Angiostatin and anti-angiogenic therapy in human disease. Recent Prog Horm Res 2004; 59:73-104.
42. Yang H, Nie X, Dithmar S, Berglin CL, Grossniklaus HE. Vascular endothelial growth factor (VEGF)/pigment epithelium derived factor (PEDF) balance in uveal melanoma. ARVO Annual Meeting; 2004 April 25-29; Fort Lauderdale (FL).
43. LeCouter J, Moritz DR, Li B, Phillips GL, Liang XH, Gerber HP, Hillan KJ, Ferrara N. Angiogenesis-independent endothelial protection of liver: role of VEGFR-1. Science 2003; 299:890-3.